510(k) device
Resolv Endoscopic Hemostat System
Hemostasis, LLC · Hemostatic Device For Endoscopic Gastrointestinal Use (QAU, Class II) · First FDA decision Jul 26, 2024, newest Jul 26, 2024Gastrointestinal bleeding
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Resolv"
MAUDE reports
0
Brand "Resolv", since 2015
PubMed studies
18
Mentioning "Resolv"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Resolv Endoscopic Hemostat System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K234131 · Decided Jul 26, 2024 · 211 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Resolv", any status and sponsor, newest update first.
R3 Vascular Inc.Not on our public-company list
NCT04912323 · 30 participants (planned) · Start Aug 17, 2021 · Primary completion Dec 31, 2026
Device: Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold · For: Peripheral Arterial Disease; Atherosclerotic Lesion; Lower Extremity Ischemia and 1 more
Sites: Graz, Austria; Montreal, Canada; Québec, Canada · 7 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Resolv", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QAU
1,141 reports: 957 malfunction, 175 injury, 9 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Resolv"[tiab]. The summary above synthesizes these.
- Predicting solvation free energies with an implicit solvent machine learning potential.
Röcken S, Burnet AF, Zavadlav J · J Chem Phys · 2024
- Single-center, prospective study evaluating safety and efficacy of a new endoscopic hemostat system in non-variceal upper gastrointestinal bleeding.
Rughwani H, Garg R, Habeeb MF, et al. · Endosc Int Open · 2025
- Nanosizing drug particles in supercritical fluid processing.
Pathak P, Meziani MJ, Desai T, et al. · J Am Chem Soc · 2004Research Support, Non-U.S. Gov't
- Utilization of RESOLV with polymer to produce prazosin hydrochloride nanoparticles and optimization of the process parameters.
Ansari E, Honarvar B, Sajadian SA, et al. · Sci Rep · 2024
- In vitro flow diversion effect of the ReSolv stent with the shelf technique in a bifurcation aneurysm model.
Belanger BL, Morrish R, McClarty D, et al. · J Neurointerv Surg · 2024
- The formation of fluorinated tetraphenylporphyrin nanoparticles via rapid expansion processes: RESS vs RESOLV.
Sane A, Thies MC · J Phys Chem B · 2005
- Antioxidant activities of curcumin and ascorbyl dipalmitate nanoparticles and their activities after incorporation into cellulose-based packaging films.
Sonkaew P, Sane A, Suppakul P · J Agric Food Chem · 2012Research Support, Non-U.S. Gov't
- "Resolv'd to drink no more": addiction as a preindustrial construct.
Warner J · J Stud Alcohol · 1994Biography, Historical Article
- Polymeric nanoparticles from rapid expansion of supercritical fluid solution.
Sun YP, Meziani MJ, Pathak P, et al. · Chemistry · 2005
- [Experimental study of eliminat dampness resolv phlegm method in treating cervical spondylopathy of the vertebral artery type].
Zhang CW, Wu JJ, Han Y, et al. · Zhongguo Gu Shang · 2010English Abstract
- Nanosized paclitaxel particles from supercritical carbon dioxide processing and their biological evaluation.
Pathak P, Prasad GL, Meziani MJ, et al. · Langmuir · 2007Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- Angiographic Safety and Efficacy of the ReSolv Flow-Diverting Stent in a Rabbit Model.
Morrish RE, Chunta AT, Belanger BL, et al. · Interv Neuroradiol · 2026
Other devices of this type
Also filed under product code QAU.
- Hemospray Endoscopic Hemostat (HEMO-[X])Wilson-Cook Medical, Inc. · De Novo 2026
- PuraStat3-D Matrix Europe SAS · 510(k) 2026
- NexpowderNextbiomedical Co., Ltd. · 510(k) 2024
- PuraStat GI3-D Matrix, Inc. · 510(k) 2026
- PuraStat3-D Matrix, Inc. · 510(k) 2023
- PuraStat-GI3-D Matrix, Inc. · 510(k) 2021
- EndoClotEndoclot Plus Co., Ltd. · 510(k) 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.